Table 2 Demographic profile of patients with remission (n = 17) and those without remission (n = 25) at week 22.

From: Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis

Characteristic

Remission, n (%)

No remission, n (%)

OR (95% CI)

P value

Age ≥ 40 years

6 (35.3)

16 (64)

0.31 (0.08–1.11)

0.072

Male sex

8 (47.1)

8 (32)

1.89 (0.53–6.73)

0.326

Age at diagnosis ≥ 40 years

4 (23.5)

12 (48)

0.33 (0.08–1.31)

0.115

Duration of disease ≥ 10 years

4 (23.5)

11 (44)

0.39 (0.10–1.54)

0.180

Smoking

1 (5.9)

6 (24)

0.20 (0.02–1.82)

0.152

Extensive colitis

8 (47.1)

19 (76)

0.28 (0.07–1.05)

0.060

Mayo score*

7.29

8.44

0.50 (0.29–0.86)

0.009

MES*

2.12

2.36

0.24 (0.04–1.28)

0.086

CRP (mg/dL)*

0.83 ± 0.10

2.90 ± 2.98

0.64 (0.30–1.37)

0.249

Hemoglobin concentration (g/dL)*

13.6 ± 1.18

11.9 ± 2.35

1.33 (0.98–1.81)

0.071

Concomitant medication

 Systemic corticosteroids

2 (11.8)

14 (56)

0.11 (0.02–0.56)

0.008

 ≥ 20 mg/day

1 (5.9)

5 (20)

0.25 (0.03–2.36)

0.226

 5-Aminosalicylates

6 (35.3)

5 (20)

2.18 (0.54–8.82)

0.273

 Immunosuppressants

3 (17.6)

9 (36)

0.38 (0.09–1.69)

0.204

Prior use of biologics

9 (52.9)

10 (40)

1.69 (0.49–5.85)

0.410

RHI*,**

15.1 ± 7.2

15.0 ± 9.3

1.00 (0.93–1.08)

0.975

Lymphocytic cryptitis*,**

1.31 ± 0.48

1.17 ± 0.64

1.58 (0.51–4.91)

0.431

  1. OR Odds ratio, CI Confidence interval, MES Mayo endoscopic subscore, RHI Robart histopathology index.
  2. *Continuous variables are summarized as mean and standard deviation.
  3. **Two samples which did not have epithelium were omitted from the analysis (total of 40 samples were evaluated).
Back to article page